In their open-label trial, Tang et al. treated individuals with type 2 diabetes with liraglutide vs insulin, resulting in comparable improvement in glycaemic control among treatment arms, and no between-group difference in liver fat fraction [15]. The gene discussed is INS; the disease is type 2 diabetes mellitus.